Need a Nexus Letter for Sarcoidosis?
REE Medical connects veterans with pulmonologists and internal medicine specialists who understand VA rating criteria for granulomatous conditions. A strong nexus covers active vs. inactive disease status, pulmonary function, and PACT Act exposure documentation.
Explore REE Medical's Nexus Services →claim.vet may receive a referral fee if you use this link. Veterans never pay more.
Sarcoidosis is a systemic inflammatory disease characterized by the formation of granulomas — clusters of immune cells — in affected organs. The lungs and lymph nodes are most commonly involved (over 90% of cases), but sarcoidosis can affect virtually any organ: the skin, eyes, heart, liver, kidneys, nervous system, and joints.
The exact cause of sarcoidosis remains incompletely understood, but current evidence points to an abnormal immune response triggered by environmental antigens — dusts, chemicals, or infectious agents — in genetically susceptible individuals. This etiology is directly relevant to veterans' claims because military service exposes service members to a wide range of environmental triggers: burn pit smoke, jet fuel exhaust, silica dust from desert sand, beryllium from certain metals, and organic dusts from construction and demolition.
Sarcoidosis presents across a wide clinical spectrum. Some veterans have mild, self-limiting disease that resolves without treatment. Others develop chronic, progressive disease with significant pulmonary fibrosis, cardiac involvement, or neurosarcoidosis that is permanently disabling. VA's rating system attempts to capture this variability through the active/inactive distinction and objective pulmonary function measurement.
Radiologically, pulmonary sarcoidosis is staged 0 through IV:
Stage IV disease is irreversible and typically associated with significant pulmonary function impairment. Veterans with Stage IV sarcoidosis should be rated at the highest applicable percentage under DC 6846 based on their pulmonary function test results.
VA rates sarcoidosis under 38 CFR Part 4, Diagnostic Code 6846. The rating structure has two major branches: active disease and inactive disease. Understanding this distinction is critical to building your claim correctly.
| Rating | Criteria Under DC 6846 |
|---|---|
| 100% | Active sarcoidosis with chronic congestive heart failure; or; workload of 3 METs or less resulting in dyspnea, fatigue, angina, dizziness, or syncope; or; left ventricular dysfunction with ejection fraction less than 30 percent |
| 60% | Minimum rating when active, with or without treatment |
| 30% | Inactive; one to two episodes in previous 12 months; or; treatment with drugs with serious adverse effects |
| 10% | Inactive; residuals of sarcoidosis (asymptomatic but with residual scarring or organ damage); or; one episode treated in previous 12 months without adverse effects |
| 0% | Inactive; asymptomatic; no residuals |
The most important determination in a sarcoidosis rating is whether the disease is currently active. "Active" means ongoing granulomatous inflammation — evidenced by elevated serum ACE levels, active radiographic findings, ongoing symptoms, or current treatment. If your pulmonologist is managing your sarcoidosis with corticosteroids, immunosuppressants, or biologics, that is active disease for VA purposes — minimum 60%.
One of the most veteran-favorable aspects of DC 6846 is the minimum 60% rating for active sarcoidosis — with or without treatment. This means that if your sarcoidosis is currently symptomatic, being monitored actively, or requiring any ongoing management, VA must rate you at no less than 60%. Veterans who receive only 10% or 30% ratings when their sarcoidosis is still active should file for an increased rating.
When sarcoidosis significantly affects the lungs, VA may also rate pulmonary manifestations under the general rating formula for interstitial lung diseases (38 CFR Part 4, DC 6825 criteria by analogy, or use the pulmonary function tables). The key is to ensure the rating method most favorable to the veteran is applied. If pulmonary function testing shows FEV-1 below 40% predicted or DLCO below 40% predicted, a 100% rating is supportable.
For veterans with pulmonary sarcoidosis, objective pulmonary function tests (PFTs) are the foundation of the rating. VA raters use specific thresholds from 38 CFR Part 4 to assign ratings for respiratory conditions. The relevant measurements are:
| Test | What It Measures | Significance for Rating |
|---|---|---|
| FEV-1 | Forced expiratory volume in 1 second | Obstructive defect; <40% predicted → 100% |
| FVC | Forced vital capacity | Restrictive defect; <50% predicted → severe |
| FEV-1/FVC | Ratio of FEV-1 to FVC | Distinguishes obstructive vs restrictive |
| DLCO | Diffusing capacity (carbon monoxide) | Gas exchange; <40% predicted → 100% |
| SpO2/PaO2 | Oxygen saturation at rest and exercise | Need for O2 therapy → 100% |
Sarcoidosis typically causes a restrictive pattern on PFTs — reduced FVC and TLC with preserved FEV-1/FVC ratio — because granulomatous inflammation and fibrosis reduce lung compliance. In some cases, particularly with endobronchial disease, an obstructive pattern may also be present.
VA C&P examiners may perform cursory spirometry without measuring DLCO. DLCO is critical for sarcoidosis because interstitial involvement primarily impairs gas transfer, which spirometry alone may underestimate. If your C&P exam did not include DLCO, submit a private PFT that includes it. A DLCO below 50% predicted indicates moderate-to-severe impairment; below 40% supports a 100% rating under the general respiratory rating formula.
For veterans with cardiac sarcoidosis or significant pulmonary involvement, a formal exercise tolerance test (ETT or cardiopulmonary exercise test) measuring METs capacity is important. A documented workload of 3 METs or less with dyspnea or syncope supports a 100% rating under DC 6846's cardiac branch. Don't let VA underrate cardiac sarcoidosis as merely a "secondary condition" without full evaluation.
The Sergeant First Class Heath Robinson Honoring our Promise to Address Comprehensive Toxics (PACT) Act, signed August 10, 2022, created one of the most significant expansions of VA presumptive service connection in decades. For veterans with sarcoidosis, the PACT Act is transformative.
The PACT Act's burn pit and airborne hazard presumptions apply to veterans who served on active duty in covered locations and time periods, including:
Prior to the PACT Act, veterans with sarcoidosis needed a medical nexus opinion establishing that their specific exposure during service caused their granulomatous disease — a difficult argument given sarcoidosis's incompletely understood pathogenesis. The PACT Act changed this by creating a presumptive service connection for certain conditions including granulomatous disease (which encompasses sarcoidosis) in veterans with covered exposures.
Under 38 CFR § 3.307 as amended by the PACT Act, covered veterans are presumed to have been exposed to burn pits and airborne hazards, and certain respiratory and granulomatous conditions are presumed to be related to that exposure. Veterans should file a claim asserting the PACT Act presumption and provide their deployment records confirming service in a covered location.
If you are a post-9/11 veteran or Gulf War veteran with sarcoidosis who has not yet filed or has been denied service connection, file now and cite the PACT Act presumption. Submit your DD-214, any deployment records, and a clear statement that you served in a covered location. VA is required to adjudicate existing claims under the PACT Act criteria even without a specific request.
Veterans who do not qualify under the PACT Act presumption — Cold War service, Korea, Vietnam, stateside service — must establish service connection through the traditional direct service connection pathway. This requires a nexus opinion. See the section below on service connection without a presumption.
For veterans outside the PACT Act coverage window, service connection for sarcoidosis requires the standard three-element showing under 38 CFR § 3.303:
The medical literature identifies several environmental triggers associated with sarcoidosis development. Veterans whose service involved the following exposures have the strongest nexus arguments:
A nexus letter for non-PACT veterans should identify the specific in-service exposure, cite peer-reviewed literature documenting the association between that exposure and sarcoidosis, and provide an "at least as likely as not" opinion. See the nexus letter guide for detailed information on nexus documentation standards.
One of the most underutilized strategies in sarcoidosis VA claims is developing secondary condition claims. Sarcoidosis is a systemic disease that can produce ratable disabilities in multiple organ systems — each of which can be claimed and rated separately.
Cardiac involvement in sarcoidosis can cause arrhythmias (ventricular tachycardia, heart block), cardiomyopathy, and sudden cardiac death. Cardiac sarcoidosis is rated under cardiac DCs (7000 series) based on ejection fraction, METs capacity, and arrhythmia severity. Cardiac sarcoidosis with ejection fraction below 30% or METs ≤3 supports a 100% rating.
Uveitis, optic neuritis, and other ocular manifestations of sarcoidosis are rated under DC 6000-6099 based on visual acuity loss and functional impairment. Chronic uveitis can cause permanent vision loss, glaucoma, and cataracts — all of which produce additional ratable disabilities secondary to sarcoidosis.
CNS involvement includes cranial nerve palsies (especially facial nerve — Bell's palsy pattern), peripheral neuropathy, hypothalamic/pituitary involvement, and cognitive effects. Peripheral neuropathy secondary to sarcoidosis is rated under DC 8100-8730 based on severity. See our guide on lupus-related neuropathy for analogous secondary claim strategies.
Sarcoidosis granulomas produce vitamin D, leading to hypercalcemia and hypercalciuria that can cause nephrolithiasis (kidney stones) and chronic kidney disease. If your service-connected sarcoidosis has caused kidney complications, these may be rated separately under renal DCs.
Skin manifestations including lupus pernio and maculopapular rashes are rated under skin DCs based on affected body surface area. Combined with systemic sarcoidosis ratings, skin involvement can contribute meaningfully to combined disability calculations.
Chronic fatigue is among the most debilitating symptoms of sarcoidosis but is often not separately rated. Document fatigue as a symptom in your C&P exam record. If fatigue limits your ability to work, it factors into Total Disability Individual Unemployability (TDIU) consideration. See our guide on fibromyalgia for analogous fatigue documentation strategies.
Veterans with multi-system sarcoidosis face the challenge of ensuring VA evaluates and rates each manifestation appropriately. VA must rate each separately ratable condition — it cannot lump all sarcoidosis manifestations into a single DC 6846 rating if discrete organ systems produce separately ratable disabilities.
The principle from 38 CFR § 4.26 (combined ratings table) and the broader rating framework is that each disability is rated independently. If your sarcoidosis affects your lungs (DC 6846), your heart (DC 7000-series), your eyes (DC 6000-series), and your peripheral nerves (DC 8000-series), each should generate a separate rating. The combined rating formula then produces your overall disability percentage.
The anti-pyramiding rule (38 CFR § 4.14) prohibits rating the same disability or manifestations twice. For sarcoidosis, this means pulmonary manifestations rated under DC 6846 cannot also be rated separately under a pulmonary DC for the same symptoms. However, distinct organ systems — cardiac, ocular, neurological — are separate disabilities and are not pyramiding. Make sure your claim documentation clearly distinguishes which symptoms belong to which organ system involvement.
Review the Gulf War illness and undiagnosed conditions guide for related exposure documentation strategies relevant to Southwest Asia veterans.
The C&P exam for sarcoidosis should comprehensively evaluate both pulmonary and extrapulmonary involvement. Come prepared with the following:
Also review our guides on rheumatoid arthritis and lupus for additional strategies applicable to systemic inflammatory conditions — the documentation principles are highly similar.
Sarcoidosis Rating Review
Active sarcoidosis is rated at 60% minimum — but many veterans are underrated because VA misclassifies their disease as inactive. REE Medical's specialists can provide objective documentation of disease activity, pulmonary function, and secondary organ involvement to support an accurate rating.
Learn About Sarcoidosis Nexus Letters →claim.vet may receive a referral fee if you use this link. Veterans never pay more.
Editorial Standards: Written by Marcus J. Webb, veterans benefits researcher. Verified against current 38 CFR Part 4 regulations and PACT Act provisions. Last reviewed: July 2026. Not legal advice — for representation, talk to a VA-accredited attorney.
Sarcoidosis is frequently underrated. A free claim review helps you understand if you qualify for a higher rating or secondary conditions you haven't claimed.
Check My Eligibility — Free, No Phone Required →